KRAS Mutation Status in Colorectal Cancer and Treatment Response
Author Information
Author(s): Rouleau E, Spyratos F, Dieumegard B, Guinebretière J M, Lidereau R, Bièche I
Primary Institution: Centre René Huguenin, Saint Cloud, France
Hypothesis
Can KRAS mutation status in colorectal cancer more precisely predict response to EGFR targeted therapies?
Conclusion
The study suggests that additional KRAS mutations outside codons 12-13 may affect treatment response, indicating a need for more precise definitions in clinical practice.
Supporting Evidence
- 35% of the tested patients had mutations in KRAS codons 12-13.
- Two cases showed mutations in codon 19, which is not typically tested.
- Clinical studies often limit testing to codons 12-13, potentially missing other relevant mutations.
Takeaway
This study looked at how KRAS mutations in colorectal cancer can affect treatment. It found that some mutations not usually tested for might also be important.
Methodology
The study tested 70 colorectal cancer patients for KRAS mutations using high-resolution melting curve analysis followed by sequencing.
Limitations
The study primarily focused on a small sample size and may not represent the broader population.
Participant Demographics
Patients with colorectal cancer from a single genomic platform.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website